Local tumor control and treatment related toxicity after plaque brachytherapy for uveal melanoma: A systematic review and a data pooled analysis. (January 2022)
- Record Type:
- Journal Article
- Title:
- Local tumor control and treatment related toxicity after plaque brachytherapy for uveal melanoma: A systematic review and a data pooled analysis. (January 2022)
- Main Title:
- Local tumor control and treatment related toxicity after plaque brachytherapy for uveal melanoma: A systematic review and a data pooled analysis
- Authors:
- Buonanno, Francesca
Conson, Manuel
de Almeida Ribeiro, Cintia
Oliviero, Caterina
Itta, Francesca
Liuzzi, Raffaele
Pacelli, Roberto
Cella, Laura
Clemente, Stefania - Abstract:
- Highlights: EPB is the most frequently used eye-sparing treatment option for small to medium sized UMs. We present a systematic review of the literature from the last sixteen years on EPB treatment of UM. Ru-106 EPB provided high local control outcomes minimizing radiation induced complications. TCP and NTCP on pooled clinical outcomes was performed for 5-year LTC, cataract and optic neuropathy. Abstract: Uveal melanoma (UM) represents the most common primary intraocular tumor, and nowadays eye plaque brachytherapy (EPB) is the most frequently used visual acuity preservation treatment option for small to medium sized UMs. The excellent local tumor control (LTC) rate achieved by EPB may be associated with severe complications and adverse events. Several dosimetric and clinical risk factors for the development of EPB-related ocular morbidity can be identified. However, morbidity predictive models specifically developed for EPB are still scarce. PRISMA methodology was used for the present systematic review of articles indexed in PubMed in the last sixteen years on EPB treatment of UM which aims at determining the major factors affecting local tumor control and ocular morbidities. To our knowledge, for the first time in EPB field, local tumor control probability (TCP) and normal tissue complication probability (NTCP) modelling on pooled clinical outcomes were performed. The analyzed literature (103 studies including 21, 263 UM patients) pointed out that Ru-106 EPB provided highHighlights: EPB is the most frequently used eye-sparing treatment option for small to medium sized UMs. We present a systematic review of the literature from the last sixteen years on EPB treatment of UM. Ru-106 EPB provided high local control outcomes minimizing radiation induced complications. TCP and NTCP on pooled clinical outcomes was performed for 5-year LTC, cataract and optic neuropathy. Abstract: Uveal melanoma (UM) represents the most common primary intraocular tumor, and nowadays eye plaque brachytherapy (EPB) is the most frequently used visual acuity preservation treatment option for small to medium sized UMs. The excellent local tumor control (LTC) rate achieved by EPB may be associated with severe complications and adverse events. Several dosimetric and clinical risk factors for the development of EPB-related ocular morbidity can be identified. However, morbidity predictive models specifically developed for EPB are still scarce. PRISMA methodology was used for the present systematic review of articles indexed in PubMed in the last sixteen years on EPB treatment of UM which aims at determining the major factors affecting local tumor control and ocular morbidities. To our knowledge, for the first time in EPB field, local tumor control probability (TCP) and normal tissue complication probability (NTCP) modelling on pooled clinical outcomes were performed. The analyzed literature (103 studies including 21, 263 UM patients) pointed out that Ru-106 EPB provided high local control outcomes while minimizing radiation induced complications. The use of treatment planning systems (TPS) was the most influencing factor for EPB outcomes such as metastasis occurrence, enucleation, and disease specific survival, irrespective of radioactive implant type. TCP and NTCP parameters were successfully extracted for 5-year LTC, cataract and optic neuropathy. In future studies, more consistent recordings of ocular morbidities along with accurate estimation of doses through routine use of TPS are needed to expand and improve the robustness of toxicity risk prediction in EPB. … (more)
- Is Part Of:
- Radiotherapy and oncology. Volume 166(2022)
- Journal:
- Radiotherapy and oncology
- Issue:
- Volume 166(2022)
- Issue Display:
- Volume 166, Issue 2022 (2022)
- Year:
- 2022
- Volume:
- 166
- Issue:
- 2022
- Issue Sort Value:
- 2022-0166-2022-0000
- Page Start:
- 15
- Page End:
- 25
- Publication Date:
- 2022-01
- Subjects:
- Uveal melanoma -- Eye plaque brachytherapy -- Local tumor control -- Ocular morbidity -- TCP -- NTCP
Oncology -- Periodicals
Radiotherapy -- Periodicals
Tumors -- Periodicals
Medical Oncology -- Periodicals
Neoplasms -- radiotherapy -- Periodicals
Radiotherapy -- Periodicals
Radiothérapie -- Périodiques
Cancérologie -- Périodiques
Tumeurs -- Périodiques
Electronic journals
616.9940642 - Journal URLs:
- http://www.sciencedirect.com/science/journal/01678140 ↗
http://www.clinicalkey.com/dura/browse/journalIssue/01678140 ↗
http://www.clinicalkey.com.au/dura/browse/journalIssue/01678140 ↗
http://www.estro.org/ ↗
http://www.elsevier.com/journals ↗
http://www.journals.elsevier.com/radiotherapy-and-oncology/ ↗ - DOI:
- 10.1016/j.radonc.2021.11.007 ↗
- Languages:
- English
- ISSNs:
- 0167-8140
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 7240.790000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 21066.xml